Overall SNPX gets a fundamental rating of 2 out of 10. We evaluated SNPX against 525 industry peers in the Biotechnology industry. SNPX has a great financial health rating, but its profitability evaluates not so good. SNPX is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
- SNPX had negative earnings in the past year.
- In the past year SNPX has reported a negative cash flow from operations.
- In the past 5 years SNPX always reported negative net income.
- SNPX had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
- With a Return On Assets value of -84.58%, SNPX is not doing good in the industry: 69.81% of the companies in the same industry are doing better.
- SNPX has a Return On Equity of -201.09%. This is in the lower half of the industry: SNPX underperforms 68.11% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -84.58% | ||
| ROE | -201.09% | ||
| ROIC | N/A |
1.3 Margins
- SNPX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
2. Health
2.1 Basic Checks
- SNPX has more shares outstanding than it did 1 year ago.
- The number of shares outstanding for SNPX has been increased compared to 5 years ago.
- SNPX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
- SNPX has an Altman-Z score of -0.62. This is a bad value and indicates that SNPX is not financially healthy and even has some risk of bankruptcy.
- The Altman-Z score of SNPX (-0.62) is comparable to the rest of the industry.
- There is no outstanding debt for SNPX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -0.62 |
2.3 Liquidity
- SNPX has a Current Ratio of 72.70. This indicates that SNPX is financially healthy and has no problem in meeting its short term obligations.
- With an excellent Current ratio value of 72.70, SNPX belongs to the best of the industry, outperforming 99.81% of the companies in the same industry.
- A Quick Ratio of 72.70 indicates that SNPX has no problem at all paying its short term obligations.
- SNPX has a Quick ratio of 72.70. This is amongst the best in the industry. SNPX outperforms 99.81% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 72.7 | ||
| Quick Ratio | 72.7 |
3. Growth
3.1 Past
- The Earnings Per Share has grown by an impressive 73.75% over the past year.
3.2 Future
- SNPX is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 2.96% yearly.
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
3.3 Evolution
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
- SNPX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
- Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SNPX. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
5. Dividend
5.1 Amount
- No dividends for SNPX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
NYSEARCA:SNPX (1/16/2026, 8:04:00 PM)
40.5756
+1.2 (+3.04%)
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | N/A | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 8.75 | ||
| P/tB | 8.75 | ||
| EV/EBITDA | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -84.58% | ||
| ROE | -201.09% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 72.7 | ||
| Quick Ratio | 72.7 | ||
| Altman-Z | -0.62 |
TRADR 2X LONG SNPS DAILY ETF / SNPX FAQ
What does TRADR 2X LONG SNPS DAILY ETF do?
Synaptogenix, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the development of Bryostatin and Platform Drug used for the treatment of Alzheimer’s disease, Fragile X Syndrome or Autism, Multiple Sclerosis, Parkinson’s Disease, Traumatic Brain Injury, and Stroke. The company is headquartered in New York City, New York and currently employs 4 full-time employees. The company went IPO on 2020-12-07. The firm is principally focused on developing a product platform based upon a drug candidate called Bryostatin-1, which is synthesized from a natural product (bryostatin) that is isolated from a marine invertebrate organism, for the treatment of Alzheimer’s disease (AD), which is in the clinical testing stage. Preclinical studies have also demonstrated bryostatin's regenerative mechanisms of action for the rare disease Fragile X syndrome, and for other neurodegenerative disorders such as multiple sclerosis, stroke, and traumatic brain injury. The firm is also evaluating potential therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X syndrome, Multiple Sclerosis (MS), and Niemann-Pick Type C disease, which have undergone pre-clinical testing.
What is the stock price of TRADR 2X LONG SNPS DAILY ETF today?
The current stock price of SNPX is 40.5756 USD. The price increased by 3.04% in the last trading session.
What is the ChartMill technical and fundamental rating of SNPX stock?
SNPX has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 2 out of 10.